CD274 and mismatch repair cancer syndrome 1: In particular, ICIs represented by the anti-PD1/PD-L1 pathway have been most effective in patients with mismatch repair deficiency (dMMR)/MSI-H and have been approved for the second-line treatment of metastatic COAD with dMMR/MSI-H [39].